Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase

A compound according to Formula (I):

• or a pharmaceutically acceptable salt or tautomer thereof,
• wherein:
• X is NR1;
• R1 is C1-4 alkyl, C0-3 alkylene-C(O)R, or C0-3 alkylene-OC(O)R, wherein the C1-4 alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, NRN1RN2, and OH;
• R2 is H, halogen, C1-4 alkyl, or OC1-4 alkyl, wherein the C1-4 alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, NRN1RN2, and OH;
• R3 is NRN1RN2, OH, or OC1-4 alkyl;
• R4 is H, halogen, C1-4 alkyl, or OC1-4 alkyl, wherein the C1-4 alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, NRN1RN2, and OH;
• R is alkyl, heteroalkyl, alkenyl, alkynyl, NH2, O(alkyl), cycloalkyl, heterocyclyl, aryl, or heteroaryl;
• each RN1 is independently H, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;
• and
• each RN2 is independently H, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;
• with the proviso that if R3 is NH2, then R1 is not CH2CH2CH3.